近年負(fù)責(zé)的研究課題：
1. 核糖核苷酸還原酶小亞基結(jié)構(gòu)位點(diǎn)特異性抗腫瘤先導(dǎo)化合物設(shè)計(jì)與活性研究。國(guó)家自然科學(xué)基金項(xiàng)目，2009.1-2011.12。
2. 低濃度致癌物MNNG誘導(dǎo)TLS聚合酶基因表達(dá)改變的轉(zhuǎn)錄調(diào)控。國(guó)家自然科學(xué)基金項(xiàng)目，2008.1-2010.12。
3. 邵吉民研究團(tuán)隊(duì)。浙江省自然科學(xué)基金杰出人才團(tuán)隊(duì)項(xiàng)目zxtf.net.cn，2008.1-2010.12。
4. 核糖核苷酸還原酶亞基特異性抗腫瘤藥物設(shè)計(jì)與生物活性研究。浙江省科技計(jì)劃項(xiàng)目，2008.1－2010.12。
5. STAT5b 信號(hào)通路分子乙�；せ罴捌湓�乳腺癌生長(zhǎng)和轉(zhuǎn)移中作用的分子機(jī)制. 國(guó)家教育部高等學(xué)校博士學(xué)科點(diǎn)專項(xiàng)科研基金，2010.1-2012.12.
6. 環(huán)境化學(xué)污染物應(yīng)答基因的篩選鑒定和重要應(yīng)答基因的表達(dá)調(diào)控研究。973國(guó)家重點(diǎn)基礎(chǔ)研究發(fā)展規(guī)劃項(xiàng)目課題（項(xiàng)目學(xué)術(shù)骨干)，2002.12- 2008.12。
7. 人核糖核苷酸還原酶小亞基活性機(jī)制及其與小分子化學(xué)抑制物相互作用研究。國(guó)家教育部留學(xué)回國(guó)人員科研啟動(dòng)基金，2008.1-2009.12。
8. 人核糖核苷酸還原酶小亞基活性特點(diǎn)及其小分子化學(xué)抑制物選擇性作用機(jī)制。國(guó)家人事部留學(xué)回國(guó)人員科研啟動(dòng)基金，2007.1-2008.12。
9. 人核糖核苷酸還原酶小亞基活性機(jī)制及其與小分子化學(xué)抑制物相互作用的研究。浙江省留學(xué)回國(guó)人員科研啟動(dòng)費(fèi)，2006.1-2007.12.
10. 浙江大學(xué)引進(jìn)人才科研啟動(dòng)基金，2005.10。
近年代表性論文
（1) Zhu H, Fan Y, Jiang H, Shen J, Qi H, Mei R, Shao J*. Response of human DNA polymerase promoter to N-methyl-N\'-nitro-N-nitrosoguanidine. Environmental Toxicology and Pharmacology 2010;29 (1) :79–86. （*Corresponding author)
（2) Lu X#, Shao J#, Li H, Yu Y. Temporal gene expression changes induced by a low concentration of benzo[a]pyrene diol epoxide in a normal human cell line. Mutation Research 2010;684(1-2):74-80. (# Co-first authors).
（3) Zhu L, Zhou B, Chen X, Jiang H, Shao J*, Yen Y*. Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase. Biochemical Pharmacology 2009;78:1178-1185. （*Co-corresponding authors)
（4) Lu X#, Shao J#, Li H, Yu Y. Early whole-genome transcriptional response induced by benzo(a)pyrene diol epoxide in a normal human cell line. Genomics 2009; 93:332-342.
（5) Li H#, Shao J#, Lu X, Gao Z, Yu Y. Identification of early responsive genes in human amnion epithelial FL cells induced by N-methyl-N\'-nitro-N-nitrosoguanidine using oligonucleotide microarray and quantitative real-time RT-PCR approaches. Mutation Research 2008;644(1-2):1-10.zxtf.net.cn
（6) Shao J, Zhou B, Zhu L, Di Bilio A, Yen Y. A Ferrous-triapine Complex Mediates Formation of Reactive Oxygen Species That Inactivate Human Ribonucleotide Reductase. Molecular Cancer Therapeutics 2006;5(3): 586-592.
（7) Shao J, Zhou B, Chu B, Yen Y. Ribonucleotide Reductase Inhitiors and future drug design. Current Cancer Drug Targets 2006;6(5):409-431.
（8) Qiu W, Zhou B, Darwish D, Shao J, Yen Y. Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits. Biochemical and Biophysical Research Communications 2006;340(2):428-434.
（9) Zhu L, Yen Y, Shao J, Qi C, Yen C, Luo J, Zhou B. Fibroblast Growth Factor Receptor 3 Up-Regulates Vascular Endothelial Growth Factor Expression In L6 Cells. International Journal of Pharmacology 2006;2(3):324-330.
（10) Shao J, Zhou B, Zhu L, Di Bilio AJ, Su L, Yuan Y, Ren S, Lien EJ, Shih J, Yen Y. Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay. Biochemical Pharmacology 2005; 69: 627–634.
